Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Dyslipidemia caused significant (p < 0.05) increase in OS (lipid peroxidation, nitric oxide, and protein carbonyl), pro-inflammatory cytokine (CRP, IL-1β, MCP-1, and TNF-α), and eicosanoid (PGE<sub>2</sub>, LTB<sub>4</sub>, and LTC<sub>4</sub>) level in serum of both young and aged rats.
|
30535619 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we focused on the role of tumor necrosis factor alpha (TNF-α) and serum leptin and ghrelin in Diazinon (DZN)-induced dyslipidemia.
|
31153461 |
2019 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Insulin also significantly inhibited T1DM-induced hyperglycemia (p < 0.001), dyslipidemia (p < 0.0001), malondialdehyde (MDA; p < 0.0001), tumor necrosis factor-alpha (TNF-α; p < 0.001) and interleukin-6 (p < 0.001).
|
31185481 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, DISO resulted in strong inhibition against the elevation of hepatic injury marker (AST, ALT, and ALP) activities and dyslipidemia (TC, TG, LDL-C, and HDL-C), as well as liver inflammatory cytokine (IL-1, IL-6, TNF-α, and TNF-β) release in l-carnitine-fed mice (<i>p</i> < 0.05).
|
31671940 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
In baseline assessments from the CROSSROADS randomized controlled trial, serum interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and C-reactive protein (hs-CRP) were assayed in 163 older adults (37% males, 24% African American, BMI 34±3, age 70±5yrs) with hypertension, dyslipidemia and/or diabetes.
|
31781724 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
The treatment group started Van (20 mg/kg/day) treatment one-week post STZ injection and continued on Van until being sacrificed at week 10.<b>Results:</b> Administration of Van to the model group significantly (<i>p</i> < .05) ameliorated dyslipidemia and biomarkers of inflammation (TNF-α, IL-6, and hsCRP) and endothelial injury (E-selectin, P-selectin, sICAM-1, sVCAM-1, and ET-1).
|
31774317 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
It can be concluded that the genetic variant of TNF-α along with elevated TNF-α and FFA concentrations play a role in the development of dyslipidemia which could be a potent risk factor towards T2D in Gujarat population.
|
29980311 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
To mimic the inflammatory environment of COPD, two commonly used lung epithelial cell lines (BEAS-2B and A549) were treated with tumor necrosis factor (TNF), and co-treated with cholesterol/25-hydroxycholesterol (25-OH) to mimic dyslipidemia.
|
31669886 |
2019 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
The DS control group showed significant dyslipidemia, elevated malondialdehyde (MDA), tumor necrosis factor-alpha and liver fat with significant reduction in total antioxidant capacity (TAC) compared to NC.
|
30429440 |
2018 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Both exercise training for 6 weeks and carnosine treatment significantly decreased body weight gain, ameliorated obesity-induced dyslipidemia, reduced the thiobarbituric acid reactive species (TBARS) and TNF-α, while increased total antioxidant capacity and IL-10.
|
29236301 |
2018 |
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-6, TNF-α, and IL-10 levels were similar between groups; however, a positive correlation between IL-6 and CRP levels was only observed in the group with dyslipidemia (r = 0.55, p < 0.0001).
|
29516281 |
2018 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Polycystic Ovary Syndrome and Increased Soluble Tumor Necrosis Factor Like Weak Inducer of Apoptosis Levels Are Independent Predictors of Dyslipidemia in Youth.
|
27578290 |
2017 |
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.
|
29096839 |
2017 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
TNF-α, a major pro-inflammatory cytokine, was linked to various pathogenesis of diseases, including dyslipidemia.
|
28965953 |
2017 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, the -1031T>C TNFA polymorphism was associated with dyslipidemia in ACS in a Western Mexican population.
|
26618233 |
2016 |
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the homeostasis model assessment of insulin resistance (HOMA-IR) index and serum proinflammatory cytokine levels (TNF-α and IL-6) involved in dyslipidaemia was markedly improved.
|
26264374 |
2015 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our study validates the association of the TNF-α 238G/A SNP allelic variant with the development of HIV- lipodystrophy via the modulation of TNF-α production, which contributes to dyslipidemia, increased lipolysis, increased insulin resistance, altered differentiation of adipocytes and increased carotid intima thickness.
|
25439236 |
2015 |
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we investigated the impact of diabetes and dyslipidemia on VCAM-1 expression in mouse retinal vessels, as well as the potential role of tumor necrosis factor-α (TNFα).
|
20856927 |
2010 |
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Especially PAI-1 and TNFalpha accompany insulin resistance and dyslipidemia.
|
18278185 |
2008 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Especially PAI-1 and TNFalpha accompany insulin resistance and dyslipidemia.
|
18278185 |
2008 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated the contribution of APOC3 -482C-->T, -455T-->C, and 3238C-->G; epsilon 2 and epsilon 4 alleles of APOE; and TNF -238G-->A to dyslipidemia and lipoatrophy by longitudinally modeling >2600 lipid determinations and 2328 lipoatrophy assessments in 329 ART-treated patients during a median follow-up period of 3.4 years.
|
15809899 |
2005 |
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Although current evidence suggests that neutralizing TNF-alpha in type 2 diabetic subjects is not sufficient to cause metabolic improvement, it is still probable that TNF-alpha is a contributing factor in common metabolic disturbances such as insulin resistance and dyslipidemia.
|
10878750 |
2000 |